EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

Christopher Alihosseini, Hannah Kopelman iD, Mallory Zaino, Steven R Feldman iD

Annals of Pharmacotherapy · 2023

DOI: 10.1177/10600280231161592 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Christopher Alihosseini und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Osteopathic Medicine, New York Institute of Technology, Glen Head, NY, USA. Hauptthemen laut MEDLINE: Immunosuppressive Agents, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To review the safety and efficacy of avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Data Sources: A systematic review of the literature was performed using the terms avacopan OR tavneos OR CCX168 OR ANCA-associated vasculitis in PubMed and Google Scholar. Articles between January 2016 and January 2023 were considered for inclusion. Bibliographies and ClinicalTrials.gov were also searched for completion. Study Selection and Data Extraction: Relative English language and human studies related to pharmacology, clinical trials, and safety were included. Data Synthesis: The 52-week ADVOCATE and 12-week CLEAR clinical trials evaluated the safety and efficacy of avacopan. The remission rate was 65.7% and 54.9% in the avacopan and placebo group, respectively, in the ADVOCATE trial. The Birmingham Vasculitis Activity Score improved by ≥50% in 86.4% of avacopan treated patients and 70% of prednisone treated patients in the CLEAR trial. Relevance to Patient Care and Clinical Practice in Comparison With Existing Drugs: Glucocorticoids in combination with cyclophosphamide, azathioprine, and/or rituximab have been a mainstay of ANCA-associated vasculitis treatment. However, short- and long-term medication-related adverse effects risk negative outcomes for patients. Avacopan may provide equivalent to better treatment with fewer side effects due to a reduction, if not elimination, of glucocorticoids.

Conclusions

Avacopan used in isolation or combination is safe and effective for ANCA-associated vasculitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunosuppressive AgentsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansAntibodies, Antineutrophil CytoplasmicCyclophosphamideRituximabGlucocorticoidsRemission InductionAniline CompoundsNipecotic Acids

Stichwörter der Autor:innen

ANCA-associated vasculitisAutoimmuneAvacopanTAVNEOSVasculitis

Substanzen

Immunosuppressive AgentsAntibodies, Antineutrophil CytoplasmicCyclophosphamideRituximabGlucocorticoidsavacopanAniline CompoundsNipecotic Acids

Autor:innen und Institutionen

  • College of Osteopathic Medicine, New York Institute of Technology, Glen Head, NY, USA.
  • Advanced Dermatology and Cosmetic Surgery, Maitland, FL, USA.
  • Wake Forest School of Medicine, Winston-Salem, NC, USA.

ORCID-Profile: Hannah Kopelman, Steven R Feldman

Zitieren

APA

Alihosseini, C., Kopelman, H., Zaino, M., & Feldman, S. R. (2023). Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231161592

Vancouver

Alihosseini C, Kopelman H, Zaino M, Feldman SR. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280231161592

BibTeX
@article{Alihosseini2023,
  author = {Alihosseini, Christopher and Kopelman, Hannah and Zaino, Mallory and Feldman, Steven R},
  title = {Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis},
  journal = {Annals of Pharmacotherapy},
  year = {2023},
  doi = {10.1177/10600280231161592}
}
Kostenlos starten →